 Connection
Ashley Frazer-Abel to Disease Progression
This is a "connection" page, showing publications Ashley Frazer-Abel has written about Disease Progression.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.103 |
|
|
|
-
Lynch AM, Grove NC, Wagner BD, Palestine AG, Holers VM, Frazer-Abel AA, Gnanaraj R, Lisker-Cervantes A, Patnaik JL, de Carlo Forest TE, Auer EA, McReynolds AJ, Mathias MT, Manoharan N, Rodriquez De Cordoba S, Mandava N. Dynamic Risk of Systemic Complement Activation With Time to Progression to Advanced Age-Related Macular Degeneration. JAMA Ophthalmol. 2025 Aug 01; 143(8):634-642.
Score: 0.034
-
Petrow E, Feng C, Frazer-Abel A, Marangoni RG, Lutz K, Nichols WC, Holers VM, Ritchlin C, White RJ, Korman BD. Utility of factor D and other alternative complement factors as biomarkers in systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH). Semin Arthritis Rheum. 2024 12; 69:152554.
Score: 0.032
-
Bemis EA, Norris JM, Seifert J, Frazer-Abel A, Okamoto Y, Feser ML, Demoruelle MK, Deane KD, Banda NK, Holers VM. Complement and its environmental determinants in the progression of human rheumatoid arthritis. Mol Immunol. 2019 08; 112:256-265.
Score: 0.022
-
Lichtenstein KA, Armon C, Nagabhushanam V, Efaw BJ, Frazer-Abel A, Hiserote ME, Alam R. A pilot study to assess inflammatory biomarker changes when raltegravir is added to a virologically suppressive HAART regimen in HIV-1-infected patients with limited immunological responses. Antivir Ther. 2012; 17(7):1301-9.
Score: 0.014
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|